Transforming Growth Factor Beta 1 (TGFB1) – Transforming growth factor beta 1 (TGF-β1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310016 .
Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Cardiovascular, Central Nervous System, Genetic Disorders and Respiratory which include indications Fibrosis, Kidney Fibrosis, Liver Fibrosis, Acute Pain, Atherosclerosis, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Chronic Pancreatitis Pain, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hypertrophic Scars, Inflammation, Metastatic Breast Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteoarthritis, Osteogenesis Imperfecta, Proliferative Vitreoretinopathy (PVR), Pulmonary Fibrosis, Scar, Skin Inflammation, Solid Tumor and Squamous Cell Carcinoma.
The latest report Transforming Growth Factor Beta 1 (TGFB1) – Pipeline Review, H1 2017, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.
Browse the full report @ http://www.orbisresearch.com/reports/index/transforming-growth-factor-beta-1-tgfb1-pipeline-review-h1-2017 .
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
– The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
– The report reviews Transforming Growth Factor Beta 1 (TGFB1)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
– The report assesses Transforming Growth Factor Beta 1 (TGFB1)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310016 .
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1)development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Acceleron Pharma Inc
Eli Lilly and Company
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Scholar Rock Inc
For any enquires before buying, connect with us @ firstname.lastname@example.org
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact email@example.com